Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 5/2010

Open Access 01-10-2010

Intestinal Goblet Cells and Mucins in Health and Disease: Recent Insights and Progress

Authors: Young S. Kim, Samuel B. Ho

Published in: Current Gastroenterology Reports | Issue 5/2010

Login to get access

Abstract

The mucus layer coating the gastrointestinal tract is the front line of innate host defense, largely because of the secretory products of intestinal goblet cells. Goblet cells synthesize secretory mucin glycoproteins (MUC2) and bioactive molecules such as epithelial membrane-bound mucins (MUC1, MUC3, MUC17), trefoil factor peptides (TFF), resistin-like molecule β (RELMβ), and Fc-γ binding protein (Fcgbp). The MUC2 mucin protein forms trimers by disulfide bonding in cysteine-rich amino terminal von Willebrand factor (vWF) domains, coupled with crosslinking provided by TFF and Fcgbp proteins with MUC2 vWF domains, resulting in a highly viscous extracellular layer. Colonization by commensal intestinal microbiota is limited to an outer “loose” mucus layer, and interacts with the diverse oligosaccharides of mucin glycoproteins, whereas an “inner” adherent mucus layer is largely devoid of bacteria. Defective mucus layers resulting from lack of MUC2 mucin, mutated Muc2 mucin vWF domains, or from deletion of core mucin glycosyltransferase enzymes in mice result in increased bacterial adhesion to the surface epithelium, increased intestinal permeability, and enhanced susceptibility to colitis caused by dextran sodium sulfate. Changes in mucin gene expression and mucin glycan structures occur in cancers of the intestine, contributing to diverse biologic properties involved in the development and progression of cancer. Further research is needed on identification and functional significance of various components of mucus layers and the complex interactions among mucus layers, microbiota, epithelial cells, and the underlying innate and adaptive immunity. Further elucidation of the regulatory mechanisms involved in mucin changes in cancer and inflammation may lead to the development of novel therapeutic approaches.
Literature
1.
Lievin-Le Moal V, Servin AL: The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006, 19:315–337.CrossRefPubMed
2.
• Dharmani P, Srivastava V, Kissoon-Singh V, et al.: Role of intestinal mucins in innate host defense mechanisms against pathogens. J Innate Immun 2009, 1:123–135. This article provides a succinct review of the role of mucin in innate host defense against commensal and pathogenic microbiota and the role of intestinal microbes in mucin regulation.CrossRefPubMed
3.
Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4:45–60.CrossRefPubMed
4.
Andrianifahanana M, Moniaux N, Batra SK: Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. Biochim Biophys Acta 2006, 1765:189–222.PubMed
5.
• McGuckin MA, Eri R, Simms LA, et al.: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009, 15:100–113. This article provides a critical review of the components of the secreted and cellular barrier and their regulation and the evidence of barrier dysfunction in IBD.CrossRefPubMed
6.
• van der Flier LG, Clevers H: Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009, 71:241–260. This article provides a succinct summary of the current view of intestinal stem cells and genetic hierarchy responsible for cell fate commitment and differentiation in normal and diseased intestine.CrossRefPubMed
7.
Velcich A, Yang W, Heyer J, et al.: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726–1729.CrossRefPubMed
8.
Taupin D, Podolsky DK: Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003, 4:721–732.CrossRefPubMed
9.
Karam SM: Lineage commitment and maturation of epithelial cells in the gut. Front Biosci 1999, 4:D286–298.CrossRefPubMed
10.
Deplancke B, Gaskins HR: Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr 2001, 73:1131S–1141S.PubMed
11.
Stanger BZ, Datar R, Murtaugh LC, et al.: Direct regulation of intestinal fate by Notch. Proc Natl Acad Sci U S A 2005, 102:12443–12448.CrossRefPubMed
12.
Yang Q, Bermingham NA, Finegold MJ, et al.: Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. Science 2001, 294:2155–2158.CrossRefPubMed
13.
Park ET, Oh HK, Gum JR, Jr, et al.: HATH1 expression in mucinous cancers of the colorectum and related lesions. Clin Cancer Res 2006, 12:5403–5410.CrossRefPubMed
14.
Davis CW, Dickey BF: Regulated airway goblet cell mucin secretion. Annu Rev Physiol 2008, 70:487–512.CrossRefPubMed
15.
Gum JR, Byrd JC, Hicks JW, et al.: Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism. J Biol Chem 1989, 264:6480–6487.PubMed
16.
Gum JR Jr, Hicks JW, Toribara NW, et al.: Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. J Biol Chem 1994, 269:2440–2446.PubMed
17.
Godl K, Johansson ME, Lidell ME, et al.: The N terminus of the MUC2 mucin forms trimers that are held together within a trypsin-resistant core fragment. J Biol Chem 2002, 277:47248–47256.CrossRefPubMed
18.
Lidell ME, Johansson ME, Morgelin M, et al.: The recombinant C-terminus of the human MUC2 mucin forms dimers in Chinese-hamster ovary cells and heterodimers with full-length MUC2 in LS 174T cells. Biochem J 2003, 372:335–345.CrossRefPubMed
19.
Gum JR Jr, Ho JJ, Pratt WS, et al.: MUC3 human intestinal mucin. Analysis of gene structure, the carboxyl terminus, and a novel upstream repetitive region. J Biol Chem 1997, 272:26678–26686.CrossRefPubMed
20.
Gum JR Jr, Hicks JW, Crawley SC, et al.: Initiation of transcription of the MUC3A human intestinal mucin from a TATA-less promoter and comparison with the MUC3B amino terminus. J Biol Chem 2003, 278:49600–49609.CrossRefPubMed
21.
Hattrup CL, Gendler SJ: Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008, 70:431–457.CrossRefPubMed
22.
Ho SB, Dvorak LA, Moor RE, et al.: Cysteine-rich domains of muc3 intestinal mucin promote cell migration, inhibit apoptosis, and accelerate wound healing. Gastroenterology 2006, 131:1501–1517.CrossRefPubMed
23.
Luu Y, Junker W, Rachagani S, et al.: Human intestinal MUC17 mucin augments intestinal cell restitution and enhances healing of experimental colitis. Int J Biochem Cell Biol 2010, 42:996–1006.CrossRefPubMed
24.
Carlstedt I, Sheehan JK: Structure and macromolecular properties of cervical mucus glycoproteins. Symp Soc Exp Biol 1989, 43:289–316.PubMed
25.
Kim YS, Deng G: Aberrant expression of carbohydrate antigens in cancer: the role of genetic and epigenetic regulation. Gastroenterology 2008, 135:305–309.CrossRefPubMed
26.
• Brockhausen I, Schacter H, Stanley P: O-GalNAc glycans. In Essentials of Glycobiology. Edited by Varki A, Cummings RD, Esko JD. Woodbury, NY: Cold Spring Harbor Laboratory Press; 2009:115–127. This is a concise review of the structure, biosynthesis, and function of mucin O-glycans.
27.
Theodoropoulos G, Carraway KL: Molecular signaling in the regulation of mucins. J Cell Biochem 2007, 102:1103–1116.CrossRefPubMed
28.
Thai P, Loukoianov A, Wachi S, et al.: Regulation of airway mucin gene expression. Annu Rev Physiol 2008, 70:405–429.CrossRefPubMed
29.
Li J-D, Feng W, Gallup M, et al.: Activation of NF-kB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for Pseudomonas aeruginosa-induced mucin overproduction in epithelial cells. Proc Natl Acad Sci U S A 1998, 95:5718–5723.CrossRefPubMed
30.
Ahn DH, Crawley SC, Hokari R, et al.: TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem 2005, 15:29–40.CrossRefPubMed
31.
Iwashita J, Sato Y, Sugaya H, et al.: mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003, 81:275–282.CrossRefPubMed
32.
Hokari R, Lee H, Crawley SC, et al.: Vasoactive intestinal peptide upregulates MUC2 intestinal mucin via CREB/ATF1. Am J Physiol Gastrointest Liver Physiol 2005, 289:G949–959.CrossRefPubMed
33.
Gregorieff A, Stange DE, Kujala P, et al.: The ets-domain transcription factor Spdef promotes maturation of goblet and Paneth cells in the intestinal epithelium. Gastroenterology 2009, 137:1333–1345 e1331–1333.
34.
Okudaira K, Kakar S, Cun L, et al.: MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010, 36:765–775.PubMed
35.
Yamada N, Hamada T, Goto M, et al.: MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 2006, 119:1850–1857.CrossRefPubMed
36.
Atuma C, Strugala V, Allen A, et al.: The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 2001, 280:G922–G929.PubMed
37.
Johansson ME, Thomsson KA, Hansson GC: Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res 2009, 8:3549–3557.CrossRefPubMed
38.
Ho SB, Takamura K, Anway R, et al.: The adherent gastric mucous layer is composed of alternating layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci 2004, 49:1598–1606.CrossRefPubMed
39.
Phillipson M, Johansson ME, Henriksnas J, et al.: The gastric mucus layers: constituents and regulation of accumulation. Am J Physiol Gastrointest Liver Physiol 2008, 295:G806–G812.CrossRefPubMed
40.
Didierlaurent A, Sirard JC, Kraehenbuhl JP, et al.: How the gut senses its content. Cell Microbiol 2002, 4:61–72.CrossRefPubMed
41.
•• Johansson ME, Phillipson M, Petersson J, et al.: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 2008, 105:15064–15069. This article provides definitive evidences for the presence, identity, and differential microbial association of two mucus layers in mouse colon and for the defective mucus barrier, increased permeability, and susceptibility to experimental colitis in Muc2-deficient mice.CrossRefPubMed
42.
•• Martens EC, Roth R, Heuser JE, et al.: Coordinate regulation of glycan degradation and polysaccharide capsule biosynthesis by a prominent human gut symbiont. J Biol Chem 2009, 284:18445–18457. This article describes a novel regulatory pathway involving O-glycan targeting outer membrane protein on a gut bacterium that governs the coordinated regulation of O-glycan catabolism and capsule synthesis.CrossRefPubMed
43.
Van der Sluis M, De Koning BA, De Bruijn AC, et al.: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006, 131:117–129.CrossRefPubMed
44.
McAuley JL, Linden SK, Png CW, et al.: MUC1 cell surface mucin is a critical element of the mucosal barrier to infection. J Clin Invest 2007, 117:2313–2324.CrossRefPubMed
45.
• Sartor RB: Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577–594. This is a comprehensive review on intestinal commensal and pathogenic microbiota/host interactions in health and disease and in rodent models of IBD.CrossRefPubMed
46.
Frank DN, St Amand AL, Feldman RA, et al.: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104:13780–13785.CrossRefPubMed
47.
Qin J, Li R, Raes J, et al.: A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59–65.CrossRefPubMed
48.
Moncada DM, Kammanadiminti SJ, Chadee K: Mucin and Toll-like receptors in host defense against intestinal parasites. Trends Parasitol 2003, 19:305–311.CrossRefPubMed
49.
Fukata M, Abreu MT: Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol 2009, 9:680–687.CrossRefPubMed
50.
Mack DR, Michail S, Wei S, et al.: Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999, 276:G941–G950.PubMed
51.
Sherman PM, Ossa JC, Johnson-Henry K: Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009, 24:10–14.CrossRefPubMed
52.
Kjellev S: The trefoil factor family—small peptides with multiple functionalities. Cell Mol Life Sci 2009, 66:1350–1369.CrossRefPubMed
53.
Kindon H, Pothoulakis C, Thim L, et al.: Trefoil peptide protection of intestinal epithelial barrier function: Cooperative interaction with mucin glycoprotein. Gastroenterology 1995, 109:516–523.CrossRefPubMed
54.
Podolsky DK, Gerken G, Eyking A, et al.: Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009, 137:209–220.CrossRefPubMed
55.
Tomasetto C, Masson R, Linares J-S, et al.: pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology 2000, 118:70–80.CrossRefPubMed
56.
Albert TK, Laubinger W, Müller S, et al.: Human intestinal TFF3 forms disulfide-linked heteromers with the mucus-associated FCGBP protein and is released by hydrogen sulfide. J Proteome Res 2010 (Epub ahead of print).
57.
Artis D, Wang ML, Keilbaugh SA, et al.: RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci U S A 2004, 101:13596–13600.CrossRefPubMed
58.
Nair MG, Guild KJ, Du Y, et al.: Goblet cell-derived resistin-like molecule beta augments CD4+ T cell production of IFN-gamma and infection-induced intestinal inflammation. J Immunol 2008, 181:4709–4715.PubMed
59.
Hogan SP, Seidu L, Blanchard C, et al.: Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. J Allergy Clin Immunol 2006, 118:257–268.CrossRefPubMed
60.
Herbert DR, Yang JQ, Hogan SP, et al.: Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. J Exp Med 2009, 206:2947–2957.CrossRefPubMed
61.
Krimi RB, Kotelevets L, Dubuquoy L, et al.: Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. Inflamm Bowel Dis 2008, 14:931–941.CrossRefPubMed
62.
Kobayashi K, Ogata H, Morikawa M, et al.: Distribution and partial characterisation of IgG Fc binding protein in various mucin producing cells and body fluids. Gut 2002, 51:169–176.CrossRefPubMed
63.
Knight PA, Brown JK, Pemberton AD: Innate immune response mechanisms in the intestinal epithelium: potential roles for mast cells and goblet cells in the expulsion of adult Trichinella spiralis. Parasitology 2008, 135:655–670.CrossRefPubMed
64.
•• Hasnain SZ, Wang H, Ghia JE, et al.: Mucin gene deficiency in mice impairs host resistance to an enteric parasitic infection. Gastroenterology 2010, 138:1763–1771. This recent study shows that mucin is an important component of innate defense in nematode infection in resistant, susceptible, and Muc2-deficient mice.CrossRefPubMed
65.
Ishikawa N, Horii Y, Oinuma T, et al.: Goblet cell mucins as the selective barrier for the intestinal helminths: T-cell-independent alteration of goblet cell mucins by immunologically ‘damaged’ Nippostrongylus brasiliensis worms and its significance on the challenge infection with homologous and heterologous parasites. Immunology 1994, 81:480–486.PubMed
66.
Lidell ME, Moncada DM, Chadee K, et al.: Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal domain and dissolve the protective colonic mucus gel. Proc Natl Acad Sci U S A 2006, 103:9298–9303.CrossRefPubMed
67.
68.
Chin WC, Quesada I, Nguyen T, et al.: Oscillations of pH inside the secretory granule control the gain of Ca2+ release for signal transduction in goblet cell exocytosis. Novartis Found Symp 2002, 248:132–141; discussion 141–139, 277–182.CrossRefPubMed
69.
• Garcia MA, Yang N, Quinton PM: Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. J Clin Invest 2009, 119:2613–2622. This recent study provides evidence indicating that defective CFTR dependent-HCO3- secretion causes aggregated mucus in various organs in CF mice.CrossRefPubMed
70.
Thomsson KA, Hinojosa-Kurtzberg M, Axelsson KA, et al.: Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucalpha1-2 glycosyltransferase. Biochem J 2002, 367:609–616.CrossRefPubMed
71.
De Lisle RC, Roach E, Jansson K: Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2007, 293:G577–G584.CrossRefPubMed
72.
Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427–434.CrossRefPubMed
73.
•• Heazlewood CK, Cook MC, Eri R, et al.: Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med 2008, 5:e54. This report provides important evidence indicating that mucin misfolding can cause endoplasmic reticulum stress and can be a primary cause for pathogenesis of colitis.CrossRefPubMed
74.
Johansson MEV, Gustafsson JK, Sjöberg KE, et al.: Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PloS One 2010, in press.
75.
•• An G, Wei B, Xia B, et al.: Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med 2007, 204:1417–1429. This is the first report describing the causal relationship between defective O-glycan synthesis and reduced Muc2 protein, defective intestinal barrier, and increased susceptibility to experimental colitis in mice.CrossRefPubMed
76.
Stone EL, Ismail MN, Lee SH, et al.: Glycosyltransferase function in core 2-type protein O glycosylation. Mol Cell Biol 2009, 29:3770–3782.CrossRefPubMed
77.
Tanaka H, Deng G, Matsuzaki K, et al.: BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. Int J Cancer 2006, 118:2765–2771.CrossRefPubMed
78.
Kim DH, Kim JW, Cho JH, et al.: Expression of mucin core proteins, trefoil factors, APC and p21 in subsets of colorectal polyps and cancers suggests a distinct pathway of pathogenesis of mucinous carcinoma of the colorectum. Int J Oncol 2005, 27:957–964.PubMed
79.
Byrd JC, Bresalier RS: Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004, 23:77–99.CrossRefPubMed
Metadata
Title
Intestinal Goblet Cells and Mucins in Health and Disease: Recent Insights and Progress
Authors
Young S. Kim
Samuel B. Ho
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 5/2010
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-010-0131-2

Other articles of this Issue 5/2010

Current Gastroenterology Reports 5/2010 Go to the issue

ReviewPaper

Features and Management of Colonic Diverticular Disease

ReviewPaper

The Hypersensitive Esophagus: Pathophysiology, Evaluation, and Treatment Options

Clinical Trial Report

Clinical Trial Report—The Final Frontier: Small Intestine

ReviewPaper

Intestinal Stem Cells

ReviewPaper

Colon Ischemia: Recent Insights and Advances

ReviewPaper

Enteric Nervous System in the Small Intestine: Pathophysiology and Clinical Implications

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits